home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

223.47 +7.08 (+3.27%)

Official Closing Price Updated: 7:00 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

19 20 Next >

Betting on Bitcoin: Does Coinbase Stock’s Surge Signal a Buy? ↗

March 07, 2024

vBitcoin has exploded higher over the past month setting an all-time record. That’s excellent news for Coinbase Global and COIN stock.

Via InvestorPlace

Thermo Fisher Stock Lights Up The Board, Soars 40% In 5 Months ↗

March 06, 2024

Thermo Fisher stock has risen more than 40% since October. Additionally, it's closed higher nine of the past 11 trading sessions.

Via Investor's Business Daily

Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing

February 21, 2024

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

February 20, 2024

From Charles River Laboratories International, Inc.

Via Business Wire

Forecasting The Future: 4 Analyst Projections For Charles River ↗

February 15, 2024

Via Benzinga

Earnings Scheduled For February 14, 2024 ↗

February 14, 2024

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion.

Via Benzinga

9 Analysts Have This to Say About Charles River ↗

December 11, 2023

Via Benzinga

The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore. ↗

February 15, 2024

Looking for the next generational winner in healthcare stocks? These are three of the top prospects today.

Via InvestorPlace

Stocks Rebound As Investor Focus Shifts To Earnings, Bitcoin Tops $1 Trillion Value: What's Driving Markets Wednesday? ↗

February 14, 2024

The U.S. stock market attempted a rebound following Tuesday’s declines, which were sparked by a higher-than-expected inflation report in January, as investors refocused on corporate earnings.

Via Benzinga

Topics Economy

Charles River Laboratories Stock Surges On Upbeat Annual Outlook, But This Analyst Is Concerned ↗

February 14, 2024

Charles River Laboratories Q4 2023 revenue: $1.01 billion, down 7.9% YoY, beating consensus. Analysts note mixed Q4 performance, keeping Outperform rating.

Via Benzinga

Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday ↗

February 14, 2024

U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday.

Via Benzinga

Topics Stocks

Expert Ratings for Charles River ↗

November 10, 2023

Via Benzinga

Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 14, 2024

Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list...

Via Benzinga

Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test

January 29, 2024

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

January 24, 2024

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call

January 23, 2024

From Charles River Laboratories International, Inc.

Via Business Wire

Ten Big Losers To Start The Year. Tesla Isn't The Worst. ↗

January 16, 2024

Enphase Energy remains out of phase with the stock market.

Via Investor's Business Daily

Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing

January 16, 2024

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

January 08, 2024

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration

December 18, 2023

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening

December 12, 2023

From Charles River Laboratories International, Inc.

Via Business Wire

Investing in the Aging Population: 3 Healthcare Stocks to Watch ↗

December 07, 2023

America is becoming a much older country on average. These three healthcare stocks are ideally positioned for this demographic shift.

Via InvestorPlace

Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration

November 28, 2023

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Laboratories to Present at Evercore ISI Investor Conference

November 27, 2023

From Charles River Laboratories International, Inc.

Via Business Wire

The 3 Most Undervalued Tech Stocks to Buy Now: November 2023 ↗

November 17, 2023

Growth stocks are rallying but there are still bargains to be found. These three top tech picks can reward long-term investors.

Via InvestorPlace

Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products

November 16, 2023

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

November 13, 2023

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023

November 09, 2023

From Charles River Laboratories International, Inc.

Via Business Wire

Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook ↗

November 08, 2023

Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating the

Via Benzinga

Charles River Laboratories Announces Third-Quarter 2023 Results

November 08, 2023

From Charles River Laboratories International, Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com